Compare HOVR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | ACET |
|---|---|---|
| Founded | 2013 | 1947 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 69.6M |
| IPO Year | N/A | 2017 |
| Metric | HOVR | ACET |
|---|---|---|
| Price | $1.82 | $7.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $10.33 | ★ $65.33 |
| AVG Volume (30 Days) | ★ 454.6K | 130.1K |
| Earning Date | 01-01-0001 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.45 |
| 52 Week High | $4.18 | $9.05 |
| Indicator | HOVR | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 50.32 |
| Support Level | $1.70 | $6.54 |
| Resistance Level | $1.90 | $8.46 |
| Average True Range (ATR) | 0.15 | 0.48 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 27.14 | 37.93 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.